-
公开(公告)号：US11766479B1
公开(公告)日：2023-09-26
申请号：US17815367
申请日：2022-07-27
发明人： Zuoxiang Xiao , Jiaping Peng , Dongwen Zhou , Wei Zhou
CPC分类号： A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/2809 , C07K16/2896 , C07K16/40 , A61K2039/505 , C07K2317/31 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
-
公开(公告)号：US20210388118A1
公开(公告)日：2021-12-16
申请号：US17458945
申请日：2021-08-27
发明人： Weizao Chen , Yanping Wang , Zuoxiang Xiao
摘要： The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen-binding fragments and a modified Fc region to facilitate heterodimer formation In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.
-
公开(公告)号：US20240309116A1
公开(公告)日：2024-09-19
申请号：US18574000
申请日：2022-05-17
发明人： Zuoxiang Xiao , Jiaping Peng , Dongwen Zhou , Wei Zhou , Hangbin Miao , Guannv Wang
CPC分类号： C07K16/468 , A61P35/00 , A61K2039/505 , C07K2317/31 , C07K2317/565
摘要： Disclosed herein are monoclonal antibodies against ROR1, bispecific antibodies against ROR1 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and antibody-drug conjugates comprising the antibodies, and therapeutic methods for using the antibodies.
-
公开(公告)号：US20230357410A1
公开(公告)日：2023-11-09
申请号：US17312258
申请日：2019-12-20
发明人： Weizao Chen , Yanping Wang , Zuoxiang Xiao
CPC分类号： C07K16/2863 , A61P35/00 , C07K14/71 , C07K14/82 , C07K16/2809 , A61K2039/505 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/73 , C07K2317/92 , C07K2319/03 , C07K2319/30 , C07K2319/50
摘要： The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬ binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.
-
公开(公告)号：US11339218B2
公开(公告)日：2022-05-24
申请号：US16611986
申请日：2018-05-09
发明人： Weizao Chen , Tao Fu , Zuoxiang Xiao
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395 , A61K39/00
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.
-
-
-
-
搜索结果
5 条记录 (耗时 0.021 秒)
